Literature DB >> 991075

Nafoxidine--an antiestrogen for the treatment of breast cancer.

S S Legha, M Slavik, S K Carter.   

Abstract

Nafoxidine is a nonsteroidal antiestrogen available as an investigational agent from the Investigational Drug Branch of the National Cancer Institute. It has been used effectively in the treatment of breast cancer patients. A cumulative response rate of 31% is reported for a total of 200 patients treated with this drug. Most patients have been treated with a dose of 60 mg three times a day. Side effects include dryness of skin, photosensitivity reactions and, less commonly, partial hair loss. There is a strong correlation of response to nafoxidine with the presence of estrogen receptor in the tumor and also with the response to previous hormonal treatment. Nafoxidine is a useful addition to the list of hormonal treatments in the therapy of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 991075     DOI: 10.1002/1097-0142(197610)38:4<1535::aid-cncr2820380415>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Parallel synthesis of a desketoraloxifene analogue library via iodocyclization/palladium-catalyzed coupling.

Authors:  Chul-Hee Cho; Dai-Il Jung; Benjamin Neuenswander; Richard C Larock
Journal:  ACS Comb Sci       Date:  2011-07-13       Impact factor: 3.784

2.  Antioestrogenic derivatives of nafoxidine stimulate progesterone receptor synthesis in vivo [proceedings].

Authors:  K E Allen; V C Jordan
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

3.  Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.

Authors:  Wei Gao; Hongxiang Hu; Lipeng Dai; Miao He; Hebao Yuan; Huixia Zhang; Jinhui Liao; Bo Wen; Yan Li; Maria Palmisano; Mohamed Dit Mady Traore; Simon Zhou; Duxin Sun
Journal:  Acta Pharm Sin B       Date:  2022-02-23       Impact factor: 14.903

Review 4.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

5.  The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.

Authors:  C K Osborne; M Jarman; R McCague; E B Coronado; S G Hilsenbeck; A E Wakeling
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  Tamoxifen: catalyst for the change to targeted therapy.

Authors:  V Craig Jordan
Journal:  Eur J Cancer       Date:  2008-01       Impact factor: 9.162

7.  The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators.

Authors:  V Craig Jordan; Russell McDaniel; Fadeke Agboke; Philipp Y Maximov
Journal:  Steroids       Date:  2014-06-17       Impact factor: 2.668

Review 8.  The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.

Authors:  Philipp Y Maximov; Theresa M Lee; V Craig Jordan
Journal:  Curr Clin Pharmacol       Date:  2013-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.